The Science
Extra brakes for an immune system that will not stop.
Cellenkos manufactures an investigational therapy from regulatory T cells — the immune cells whose job is to calm other immune cells down — collected from donated umbilical cord blood and expanded in a laboratory.
The company has taken these cells through FDA-supervised studies in several serious diseases. It has not studied them in arthritis, joint conditions or sports injuries. This page covers both halves of that sentence, in that order.
What regulatory T cells are
The immune system has an accelerator and a brake. Most immune cells are the accelerator: they attack infection and drive inflammation — the swelling, heat and pain the body uses to deal with trouble. Regulatory T cells, usually shortened to T-regs, are the brake. Their job is to tell the rest of the immune system when to stop.
When the brakes do not work well, two things can go wrong. The immune system can turn on the body's own tissue, which is what happens in autoimmune disease. Or inflammation that started for a good reason can keep running long after it is useful. Both are understood to play a part in rheumatoid arthritis, and inflammation is also present in worn and degenerating joints.
The idea behind the therapy follows from that: if the brakes are failing, supply more working ones. Whether doing so changes the course of any joint or autoimmune condition in patients is an open question, and an untested one.
- The accelerator
- Effector immune cells. They identify threats, attack them and drive the inflammatory response.
- The brake
- Regulatory T cells. They suppress the response once it has done its work and keep the immune system off the body's own tissue.
- When the brake is inadequate
- Inflammation continues past the point of usefulness, or turns against healthy tissue. This is the imbalance the therapy is designed to address.
T-regs are not stem cells. Stem cells are unspecialised and can become other cell types. T-regs are mature immune cells with one function. The distinction matters both scientifically and legally.
How the product is made
Four characteristics define the product and shape what a study using it has to account for.
Source
Donated umbilical cord blood
The cells come from the blood remaining in the umbilical cord and placenta after a birth, donated for this purpose. They are donor cells — they do not come from the patient who receives them.
Manufacture
Separated and expanded in a laboratory
Regulatory T cells are isolated from the donated cord blood and grown under controlled conditions until there are enough for a dose. Cellenkos calls this manufacturing process the CRANE platform and was granted a United States patent covering it in November 2025.
Supply
Off-the-shelf and frozen
Because the cells come from donors rather than the patient, batches are manufactured in advance, frozen and shipped. Nothing is collected from the patient first and there is no manufacturing wait. It also means a site must handle and thaw a frozen cell product correctly, and that cell viability after thaw is measured and documented.
Design
Tissue-targeted variants
Cellenkos describes different versions of the product as designed to home to particular tissues, such as bone marrow or the nervous system. Its published studies use distinct product codes for different conditions on that basis.
Clinical track record
Every Cellenkos study to date has been conducted under FDA supervision, and every one has been in a serious or life-threatening disease. Statuses below are stated as the source material states them, with dates where dates are available.
| Condition | Product | Status |
|---|---|---|
| Aplastic anemiaThe immune system attacks the bone marrow. | CK0801 | FDA cleared a Phase 2 study in April 2026. A Phase 2 study tests whether a treatment works, after earlier testing has looked at safety.April 2026 |
| ALS (Lou Gehrig's disease)A progressive disease of the nerve cells that control movement. | CK0803 | Results published in April 2025 reported that patients' disease progressed more slowly with repeated infusions.April 2025 |
| Guillain-Barré syndromeThe immune system attacks the nerves. | CK0801 | Early safety and dosing study.Date not stated |
| MyelofibrosisA cancer of the bone marrow. | CK0804 | Early safety study, as an add-on to a standard drug.Date not stated |
| COVID-19 lung failureSevere respiratory failure caused by COVID-19. | Cord-blood T-regs | Placebo-controlled study of safety and early effect.Date not stated |
What this record establishes is narrow but real: that Cellenkos can manufacture these cells consistently, that it has taken them through the FDA's investigational process repeatedly, and that it has safety experience from administering them to patients. It does not establish anything about joint or autoimmune conditions.
Read this before anything else
What we don't know yet
There is no clinical data on this therapy in arthritis or any joint condition. None. That is the plainest way to say it, and every practice evaluating this network should start from it.
A review of Cellenkos's work found no study — completed, published or under way — in rheumatoid arthritis, psoriatic arthritis, osteoarthritis, joint pain, sports injuries or wound care. Those are the conditions this network is being built to study. The evidence for them does not exist yet.
There is a scientific rationale, and it is worth stating accurately, because a rationale is not a result.
What supports the rationale
A 2022 study of people with knee osteoarthritis found that those with fewer regulatory T cells in the lining of the knee joint tended to have worse symptoms. Separately, laboratory and animal research in rheumatoid arthritis suggests that restoring the balance between regulatory T cells and inflammation-driving immune cells can reduce joint damage.
Why that is not proof
That work describes how the disease behaves, or was done in mice. Neither establishes that an intravenous infusion of donor regulatory T cells improves joint disease in people. The step from mechanism to clinical benefit is exactly the step that has not been taken.
We do not know where the cells go
Even if these cells calm inflammation elsewhere in the body, it is not known how many reach a knee or a shoulder after being given into a vein, or what they do once there.
We do not know the regimen
The right dose for a joint condition, how often it should be given, and how long any effect might last are all unestablished. So is which of the tissue-targeted product variants would be appropriate.
Safety experience may not transfer
The existing safety data comes from patients with ALS, bone marrow disease and severe COVID-19. What counts as an acceptable risk for a patient with a life-threatening illness is not what counts as acceptable for an otherwise healthy adult with a painful knee. Safety in these conditions has to be characterised on its own terms.
This is the gap the network exists to close. The studies are designed to answer these questions properly, in the right patients, with predefined endpoints and independent oversight — rather than to assume the answers. Any practice joining should treat every joint and autoimmune use as unproven until the network's own studies report.
Three distinctions worth keeping straight
Terms that get used loosely in this field, and what they actually mean here.
T-regs are not stem cells
Stem cells are unspecialised and can develop into other cell types. Regulatory T cells are mature immune cells with a single function. Products, regulations and evidence that apply to stem cells do not automatically apply to these cells, and vice versa.
"Regenerative" is a category, not a standard
Many practices offer procedures such as platelet-rich plasma or bone marrow injections under the heading of regenerative medicine. Those are different from a laboratory-manufactured cell product, are regulated differently, and carry their own separate and mixed evidence. A good partner understands the difference and explains it to patients accurately.
Dosing for these conditions is not yet defined
Doses used in Cellenkos's studies in other conditions cannot be assumed to carry over. The dose for a joint or autoimmune study is a question for the protocol and the FDA, not an established figure. Placeholder, information still required: [TODO: confirm with Cellenkos — the intended dose and regimen for the first study in these conditions, and how it relates to doses used in the existing FDA-supervised studies.]
Questions we expect you to ask
Physicians evaluating this network should push on the science, and we would rather field hard questions early than late. The FAQ covers what a study asks of a site; a conversation covers the rest.
Become a Study Site